Mostrar el registro sencillo del ítem

dc.contributor.authorSereno, María
dc.contributor.authorGutiérrez-Gutiérrez, Gerardo
dc.contributor.authorRubio, Juan Moreno
dc.contributor.authorApellániz-Ruiz, María
dc.contributor.authorSánchez-Barroso, Lara
dc.contributor.authorCasado, Enrique
dc.contributor.authorFalagan, Sandra
dc.contributor.authorLópez-Gómez, Miriam
dc.contributor.authorMerino, María
dc.contributor.authorGómez-Raposo, César
dc.contributor.authorRodriguez-Salas, Nuria
dc.contributor.authorTébar, Francisco Zambrana
dc.contributor.authorRodriguez Antona, Cristina 
dc.date.accessioned2019-04-04T08:50:41Z
dc.date.available2019-04-04T08:50:41Z
dc.date.issued2017-01-19
dc.identifier.citationBMC Cancer. 2017;17(1):63.es_ES
dc.identifier.issn1471-2407es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/7434
dc.description.abstractBACKGROUND: Oxaliplatin is a chemotherapy agent active against digestive tumors. Peripheral neuropathy is one of the most important dose-limiting toxicity of this drug. It occurs in around 60-80% of the patients, and 15% of them develop severe neuropathy. The pathophysiology of oxaliplatin neurotoxicity remains unclear. SCN9A is a gene codifying for a subtype sodium channel (type IX, subunit α) and mutations in this gene are involved in neuropathic perception. In this study we investigated whether SCN9A genetic variants were associated with risk of neurotoxicity in patients diagnosed of cancer on treatment with oxaliplatin. METHODS: Blood samples from 94 patients diagnosed of digestive cancer that had received oxaliplatin in adjuvant or metastatic setting were obtained from three hospitals in Madrid. These patients were classified into two groups: "cases" developed oxaliplatin-induced grade 3-4 neuropathy (n = 48), and "controls" (n = 46) had no neuropathy or grade 1. The neuropathy was evaluated by an expert neurologist and included a clinical examination and classification according to validated neurological scales: National Cancer Institute Common Toxicity Criteria (NCI-CTC), Oxaliplatin-Specific Neurotoxicity Scale (OSNS) and Total Neuropathy score (TNS). Genotyping was performed for 3 SCN9A missense polymorphisms: rs6746030 (R1150W), rs74401238 (R1110Q) and rs41268673 (P610T), and associations between genotypes and neuropathy were evaluated. RESULTS: We found that SCN9A rs6746030 was associated with protection for severe neuropathy (OR = 0.39, 95% CI = 0.16-0.96; p = 0.041). Multivariate analysis adjusting for diabetes provided similar results (p = 0.036). No significant differences in neuropathy risk were detected for rs74401238 and rs41268673. CONCLUSION: SCN9A rs6746030 was associated with protection for severe oxaliplatin-induced peripheral neuropathy. The validation of this exploratory study is ongoing in an independent series.es_ES
dc.description.sponsorshipFor all the patients who accepted to participate in this investigation. Funding This work was supported by projects from the“Spanish Ministry of Economy and Competiveness”(grant number SAF2015-64850-R) and from Carlos III Health Institute project: PI12/02824es_ES
dc.language.isoenges_ES
dc.publisherBioMed Central (BMC) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCalcium channeles_ES
dc.subjectOxaliplatin neuropathyes_ES
dc.subjectSCN9Aes_ES
dc.subject.meshAdult es_ES
dc.subject.meshAged es_ES
dc.subject.meshAged, 80 and over es_ES
dc.subject.meshAntineoplastic Agents es_ES
dc.subject.meshBiomarkers, Tumor es_ES
dc.subject.meshDigestive System Neoplasms es_ES
dc.subject.meshFemale es_ES
dc.subject.meshFollow-Up Studies es_ES
dc.subject.meshHumans es_ES
dc.subject.meshLymphatic Metastasis es_ES
dc.subject.meshMale es_ES
dc.subject.meshMiddle Aged es_ES
dc.subject.meshNAV1.7 Voltage-Gated Sodium Channel es_ES
dc.subject.meshNeoplasm Staging es_ES
dc.subject.meshOrganoplatinum Compounds es_ES
dc.subject.meshOxaliplatin es_ES
dc.subject.meshPeripheral Nervous System Diseases es_ES
dc.subject.meshPolymorphism, Genetices_ES
dc.subject.meshPrognosis es_ES
dc.subject.meshSurvival Rate es_ES
dc.titleGenetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathyes_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID28103821es_ES
dc.format.volume17es_ES
dc.format.number1es_ES
dc.format.page63es_ES
dc.identifier.doi10.1186/s12885-016-3031-5es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España) 
dc.contributor.funderInstituto de Salud Carlos III 
dc.description.peerreviewedes_ES
dc.identifier.e-issn1471-2407es_ES
dc.identifier.journalBMC canceres_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de Epidemiología Genética y Moleculares_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2015-64850-Res_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI12/02824es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional